Analytical Data
-
Gene name
KRT19
- Application
-
Alternative Names
KRT19;Keratin. type I cytoskeletal 19
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P08727
-
Expression Region
1-400aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMTSYSYR QSSATSSFGG LGGGSVRFGP GVAFRAPSIH GGSGGRGVSV SSARFVSSSS SGAYGGGYGG VLTASDGLLA GNEKLTMQNL NDRLASYLDK VRALEAANGE LEVKIRDWYQ KQGPGPSRDY SHYYTTIQDL RDKILGATIE NSRIVLQIDN ARLAADDFRT KFETEQALRM SVEADINGLR RVLDELTLAR TDLEMQIEGL KEELAYLKKN HEEEISTLRG QVGGQVSVEV DSAPGTDLAK ILSDMRSQYE VMAEQNRKDA EAWFTSRTEE LNREVAGHTE QLQMSRSEVT DLRRTLQGLE IELQSQLSMK AALEDTLAET EARFGAQLAH IQALISGIEA QLGDVRADSE RQNQEYQRLM DIKSRLEQEI ATYRSLLEGQ EDHYNNLSAS KVL
-
Molecular Weight
47 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KRT19, or Keratin 19, is a type of intermediate filament protein that plays a critical role in the structure and function of epithelial cells, particularly within the contexts of tissue integrity and cellular signaling. It is a key component of the cytoskeleton, providing mechanical support and resilience to cells. Research on KRT19 has gained momentum due to its implication in various pathologies, notably in cancer diagnostics and prognostics. Elevated levels of KRT19 are often observed in certain types of cancers, including breast and lung cancer, making it a potential biomarker for disease progression and treatment response. Furthermore, KRT19 has been linked to epithelial-to-mesenchymal transition (EMT), a process associated with tumor metastasis and the acquisition of migratory properties by cancer cells. Studies investigating the recombinant expression of KRT19 are crucial for elucidating its functional roles, therapeutic targets, and interactions within cellular microenvironments. By generating recombinant KRT19 proteins, researchers aim to develop novel tools for studying its structural properties, mechanisms of action, and potential involvement in cell signaling pathways. Additionally, understanding the post-translational modifications of KRT19 may provide insights into its regulatory mechanisms in normal and pathological conditions, thus contributing to the development of targeted therapies in epithelial cancers. Overall, ongoing research in KRT19 and its recombinant forms holds promise for advancing our understanding of epithelial biology and enhancing clinical strategies for cancer management.
